RecruitingPhase 1NCT07404332

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase I Study of 5-Azacitidine Plus PD-1/PD-L1 Inhibitor in Patients With PD-1/PD-L1 Refractory Tumors

Sponsor

Mohammed Milhem

Enrollment

35 participants

Start Date

Feb 11, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Tumor Solid Tumor Locally Advanced Solid Tumor

Summary

This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 5 Azacytidine, a drug called Cemiplimab, and others for people with locally advanced solid tumor, metastatic tumor, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG5 Azacytidine

5-Azacitidine (Azacitidine) is a nucleoside analogue chemotherapy drug

DRUGPembrolizumab

Pembrolizumab is a high-affinity humanized monoclonal antibody that functions as immune checkpoint inhibitor

DRUGNivolumab

Nivolumab is a high-affinity humanized monoclonal antibody that functions as immune checkpoint inhibitor

DRUGCemiplimab

Cemiplimab is a high-affinity humanized monoclonal antibody that functions as immune checkpoint inhibitor

Locations(1)

University of Iowa Health Care

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07404332

Related Trials

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT0493961041 locations

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT064753001 location

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT0591926433 locations

Imaging of Solid Tumors Using 18F-TRX

NCT069421041 location